Abstract
Background Despite recommendations regarding prompt treatment of cases and enhanced hygiene measures, scarlet fever outbreaks increased in England between 2014-2018.
Methods We undertook a prospective, intensive contact tracing study in schools with consecutive scarlet fever cases to assess the impact of standard interventions on transmission of Streptococcus pyogenes between cases, classroom contacts, households, and classroom environments over 4 weeks using genome sequencing.
Findings Six classes, comprising 12 scarlet fever cases, 17 household contacts, and 278 classroom contacts were recruited. Prevalence of the outbreak strain in asymptomatic classroom contacts was high, increasing from 9.6% in week 1, to 26.9% in week 2, 23.9% in week 3, then 14.3% in week 4. Colonisation with non-outbreak strains was 0 - 7.5%. Genome sequencing showed clonality of isolates within each of six classes, confirming recent transmission accounted for high carriage. Of asymptomatic classroom contacts with S. pyogenes-positive throat swabs who were tested for transmissibility, 6/28 (21%) had positive cough plates and/or hand swabs, of whom three remained S. pyogenes-positive for 3 weeks. Only 1/60 surface swabs taken in 3 classrooms yielded S. pyogenes. In contrast, settle plates placed in elevated locations were S. pyogenes-positive in both classrooms tested.
Interpretation S. pyogenes transmission in schools is intense and may occur prior to, or in spite of reported treatment of cases, underlining a need for rapid case management. Despite guideline adherence, heavy shedding of S. pyogenes by small numbers of classroom contacts may perpetuate outbreaks, and airborne transmission has a plausible role in spread.
Funding Action Medical Research, UKRI, NIHR
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN13773960
Funding Statement
This work was funded by the following research grants awarded to Imperial College London: Action Medical Research (GN2596); UKRI, Medical Research Council (MR/P022669/1); NIHR Health Protection Research Unit in Healthcare-associated Infection and AMR; NIHR Imperial College Biomedical Research Centre (BRC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by a Research Ethics Committee (London Chelsea REC reference 18/LO/0025; IRAS 225006). Informed consent was provided by parents or guardians, and assent provided by each child.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data pertaining to the study is included in the supplementary files and genomics data is available via the European Nucleotide Archive, under the accession number PRJEB43915
